Amenorrhea following chemotherapy for the treatment of breast carcinoma: a suitable criterion of ovarian insufficiency?
Willemse, P.H.; Sleijfer, D.T.; Brouwers, T.M.; van der Ploeg, E.; Doorenbos, H.
Nederlands Tijdschrift Voor Geneeskunde 125(20): 775-779
1981
ISSN/ISBN: 0028-2162 PMID: 7242729 Document Number: 171015
Document emailed within 1 workday
Related Documents
Brachetti, A.K.; Limburg, H. 1977: Ancillary chemotherapy in the primary treatment of carcinoma of the breast. on the growth pattern of carcinoma of the breast and the establishment of a new concept in treatment Geburtshilfe und Frauenheilkunde 37(2): 109-114Zamurovic, M.; Jurisic, A.; Andjelic, S. 2010: Systemic chemotherapy--before or after radical surgery in treatment of patients with advanced ovarian carcinoma? European Journal of Gynaecological Oncology 31(5): 564-566
Conti, F.; Vici, P. 2003: Chemotherapy in the treatment of breast carcinoma Tumori 89(4 Suppl): 181-182
Pietrzak, K.; Sablińska, B.; Zieliński, J. 1993: Clinical analysis and evaluation of the results of adjuvant treatment (radiotherapy and chemotherapy) in ovarian carcinoma European Journal of Gynaecological Oncology 14(Suppl): 133-139
Nishikawa, A.; Hashimoto, H.; Takeda, M.; Kontani, K.; Miyatake, T.; Mimura, M.; Nagamatsu, M.; Yokoi, T. 2016: Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy European Journal of Gynaecological Oncology 37(4): 451-454
Sismondi, P.; Zola, P.; Galletto, L.; De Giovanni, D.; Giardina, G. 1979: Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles Minerva Ginecologica 31(7-8): 563-568
Van-Look, P., F.A.; Von-Hertzen, H. 1998: The World Health Organization Multinational Study of breast-feeding and lactational amenorrhea: II. Factors associated with the length of amenorrhea Fertility and Sterility 70(3): 461-471
Van-Look, P., F.A.; Von-Hertzen, H. 1998: The World Health Organization Multinational Study of breast-feeding and lactational amenorrhea: II. Factors associated with the length of amenorrhea Fertility and Sterility 70(3): 461-471
Van-Look, P., F.A.; Von-Hertzen, H. 1998: The World Health Organization Multinational Study of breast-feeding and lactational amenorrhea: II. Factors associated with the length of amenorrhea Fertility and Sterility 70(3): 461-471
Kaminer, L.S.; Williams, S.F.; Beschorner, J.; O'Brien, S.; Golick, J.; Bitran, J.D. 1989: High dose chemotherapy with autologous hematopoietic stem cell support in the treatment of refractory stage IV breast carcinoma Bone Marrow Transplantation 4(4): 359-362
1996: Chemotherapy of ovarian and breast cancer with Taxol Deutsche Medizinische Wochenschrift 121(50 Suppl): 1-12
Thigpen, J.T.; Vance, R.B.; Lambuth, B.W. 1988: Ovarian carcinoma: the role of chemotherapy Seminars in Oncology 15(3 Suppl 3: 16-23
Bruntsch, U.; Gallmeier, W.M. 1983: Chemotherapy of epithelial ovarian carcinoma Münchener Medizinische Wochenschrift 125(44): 993-995
Neijt, J.P.; Barents, J.W.; Vendrik, C.P.; van Lindert, A.C.; Struyvenberg, A.; Pinedo, H.M. 1980: Chemotherapy of stage IIi and IV ovarian carcinoma Nederlands Tijdschrift Voor Geneeskunde 124(38): 1601-1605
Runhaar, E.A.; van Oosterom, A.T.; de Bruijn, E.A.; ten Bokkel Huinink, W.W. 1987: Intraperitoneal chemotherapy in ovarian carcinoma Netherlands Journal of Medicine 30(1-2): 94-103
Hooning, M.J.; van Dongen, J.A.; Went, G. 1991: Changing indications for breast conserving therapy: proportion of patients with operable breast cancer suitable for breast conservation Netherlands Journal of Surgery 43(4): 102-104
Zakrzewska, I.; Poznański, J. 2001: Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 11(63): 210-213
Priolo, D.; Antonelli, G.; Calì, S.; Colina, P.; Giuffrida, D.; Malaponte, E.; Mattina, M.; Parisi, A.; Sambataro, D.; Vitale, F.; Ferraù, F. 2001: Second-line chemotherapy and new drugs for ovarian carcinoma La Clinica Terapeutica 152(1): 39-50
Biesma, B.; Willemse, P.H.; Vellenga, E.; Limburg, P.C.; Aalders, J.G.; de Vries, E.G. 1991: The hematopoietic growth factor GM-CSF in chemotherapy for ovarian carcinoma Nederlands Tijdschrift Voor Geneeskunde 135(10): 420-424
Van der Heiden-van der Loo, M.; Ho, V.K.Y.; Damhuis, R.A.M.; Siesling, S.; Menke, M.B.E.; Peeters, P.H.M.; Rutgers, E.J.T. 2010: Percentage of local recurrence following treatment for breast cancer is not a suitable performance indicator Nederlands Tijdschrift Voor Geneeskunde 154: A1984